Could MAJI Be Building the Next Basepaws? A Deep Dive Into Veterinary Oncology's Next Growth Story

On July 28, 2026, NexTel Medical Corp. (OTC: MAJI) announced a major commercial expansion into veterinary oncology — bringing its proprietary exosome-based cancer screening platform to companion animals. This is not a pivot. This is a natural extension of technology already proven in human diagnostics, now pointed at a market that is larger, faster-growing, and dramatically underserved.

The companion animal cancer diagnostics market represents one of the most compelling white spaces in all of healthcare. Twelve million dogs and cats are diagnosed with cancer in the United States every year. Fifty percent of dogs over age 10 will develop cancer. And yet early-stage screening for pets remains largely inaccessible — expensive, invasive, and rarely integrated into routine annual wellness exams.

MAJI is entering this market with something most early-stage OTC companies never have: infrastructure already in place. The NueVistraMed network spans 1,850+ digital and physical medical clinics. The JumpstartRx telehealth platform is live. The laboratory processing infrastructure is operational. The distribution moat was built for human diagnostics — and it transfers directly to veterinary applications.

The global veterinary oncology market is estimated at $2.0B–$2.9B annually. North America accounts for over 50% of total global spend — representing a $1.0B–$1.4B addressable market for a company with domestic distribution infrastructure. This is not a niche. This is a category.

The patient population is staggering. Roughly 12 million dogs and cats are diagnosed with cancer in the United States every year. Approximately 1 in 4 dogs will develop cancer in their lifetime — a figure that rises to nearly 1 in 2 for dogs over age 10. Cats face similar odds: approximately 1 in 5 will develop cancer, with lymphoma representing a widespread challenge. Beyond dogs and cats, small domestic pets including rabbits, ferrets, and rodents experience disproportionately high tumor incidence rates — presenting further expansion potential.

The structural opportunity is even more compelling than the raw numbers suggest. Early-stage cancer screening for companion animals is not yet a standard component of annual veterinary wellness exams. There is no dominant, accessible, non-invasive screening platform in the market. MAJI's stated strategy — positioning its screening as a routine annual checkup component — would create a recurring, predictable revenue stream while simultaneously advancing standard-of-care practices across the entire companion animal health sector.

In 2019, a startup called Basepaws appeared on Shark Tank pitching at-home genetic testing kits for cats. Kevin O'Leary invested $125,000 for a 5% stake — valuing the company at $2.5 million. Three years later, Zoetis — the animal health company with an $80 billion market capitalization — acquired Basepaws for an estimated $50M–$93M. O'Leary's return: 20x to 35x on his investment.

The Basepaws story is not just a feel-good Shark Tank exit. It is a proof-of-concept for the entire thesis: that proprietary diagnostic technology applied to companion animal health, with the right distribution, commands institutional-grade acquisition premiums. Zoetis did not buy Basepaws for its current revenue. It bought the technology, the data, and the market position.

The Basepaws acquisition validated the entire category. Zoetis — a company that could have built its own genetic testing platform — chose to acquire instead. That is the signal. When a strategic acquirer with an $80 billion market cap pays $50M–$93M for a startup with $3.5M in trailing revenue, it is paying for the technology, the IP, and the market position. MAJI is building all three.

MAJI's veterinary oncology platform is built on the same proprietary NANOG DNA assay that powers its human diagnostic products. This is a non-invasive liquid biopsy — a blood draw, not a biopsy needle. The company will process all diagnostic samples centrally in its specialized laboratory, collaborating with veterinary oncologists nationwide to collect and screen blood samples against diverse cancer profiles.

The technology moat here is meaningful. Exosome-based diagnostics represent a genuinely differentiated approach to cancer screening. Exosomes — nanoscale vesicles released by cells — carry molecular cargo that reflects the health status of the originating tissue. The NANOG assay is designed to detect cancer-associated biomarkers in this exosomal cargo, enabling early-stage detection before conventional imaging or symptomatic presentation.

Applied to veterinary oncology, this technology addresses a specific clinical gap: most companion animal cancers are diagnosed late, when treatment options are limited and outcomes are poor. A non-invasive, blood-based screening tool that can be administered during a routine annual wellness exam changes the clinical calculus entirely — and creates a recurring revenue model that does not depend on sick animals, only on healthy ones getting their annual checkup.

The single most important sentence in the July 28 press release is this: MAJI will process all diagnostic samples centrally in its specialized laboratory, collaborating closely with veterinary oncologists nationwide to collect and screen blood samples. The laboratory already exists. The clinical network already exists. The distribution infrastructure was built for human diagnostics — and it is being redirected into veterinary oncology.

This is the structural advantage that Basepaws did not have at launch. Basepaws started with $200,000 in sales and a direct-to-consumer model. MAJI is entering veterinary oncology with 1,850+ digital and physical medical clinics in the NueVistraMed network, an operational telehealth platform in JumpstartRx, and a laboratory already processing samples. The distribution moat was built — it just needs to be pointed at a new market.

The veterinary oncology revenue model is structurally superior to most OTC healthcare plays. MAJI is not selling a one-time product — it is positioning its screening as a routine annual wellness component. Every dog and cat that gets an annual checkup is a potential recurring revenue event. The per-test economics compound across a patient population of tens of millions.

The company's stated goal is to make early cancer screening a seamless, standard component of every pet's annual wellness exam. That framing is strategically important. It is not positioning this as a specialty oncology service — it is positioning it as a commodity wellness product. Commodity wellness products at scale generate predictable, recurring revenue. That is the revenue model Zoetis paid $50M–$93M to acquire in Basepaws.

This is an OTC Pink Sheet company. The risk profile is elevated by definition. Investors should size positions accordingly and treat this as speculative capital.

The veterinary oncology announcement is the most strategically significant press release MAJI has issued. Not because it generates revenue today — it does not. But because it demonstrates that the company's technology platform has genuine horizontal applicability, and that the distribution infrastructure built for human diagnostics has direct veterinary utility.

The Basepaws parallel is instructive but not deterministic. Basepaws was acquired because Zoetis wanted the technology, the data, and the market position — not the revenue. MAJI is building all three. The question is execution: can a small OTC company simultaneously manage a launched human diagnostic product, a veterinary oncology expansion, a telehealth platform, and a clinical network? That is the risk. The opportunity is real.

What makes this moment different from most OTC announcements is the infrastructure argument. MAJI is not announcing a plan to build distribution. It is announcing a plan to redirect existing distribution. The lab is operational. The clinical network is live. The technology is proven in human applications. The veterinary oncology market is $1.2B+ in North America alone. The Basepaws exit proved the category commands institutional acquisition premiums.